Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LIEBERMAN, A.
Right arrow Articles by LEIBOWITZ, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LIEBERMAN, A.
Right arrow Articles by LEIBOWITZ, M.
NEUROLOGY 1975;25:911
© 1975 American Academy of Neurology

Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease

ABRAHAM LIEBERMAN, M.D., ALBERT GOODGOLD, M.D., SARAN JONAS, M.D. and MORTON LEIBOWITZ, M.D.

Department of Neurology (Drs. Lieberman, Goodgold, and Jonas) and the Department of Medicine (Dr. Leibowitz), New York University School of Medicine, New York.

A double-blind study comparing the effects of carbidopa and levodopa combined in a single tablet with levodopa alone was undertaken in 50 patients with Parkinson's disease. After 6 months, there was a statistically significant improvement over baseline in total score, rigidity, and tremor only in the patients randomized to carbidopa/levodopa. In addition, 40 percent of the patients treated with carbidopa/levodopa showed obvious clinical improvement (a greater than 50 percent reduction in their total score) over treatment with levodopa alone. However, after 2 years, only 20 percent continued to show this improvement. Nausea, vomiting, and anorexia developed in 56 percent of patients on levodopa but in only 27 percent of patients on carbidopa/levodopa. However, abnormal involuntary movements, observed in 48 percent of patients on levodopa, were present in 77 percent of patients on carbidopa/levodopa. Despite the increase in abnormal involuntary movements, carbidopa/levodopa is more effective than levodopa.

Received for publication January 27, 1975.

Reprint requests should be addressed to Dr. Lieberman, 566 First Avenue, New York, NY 10016.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by AAN Enterprises, Inc.